thalidomide has been researched along with Head and Neck Neoplasms in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)." | 9.10 | Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003) |
| "An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)." | 5.10 | Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003) |
| "Lenalidomide is an immunomodulatory agent with the capacity to stimulate immune cell cytokine production and ADCC activity." | 2.82 | A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. ( Bertino, EM; Carson, WE; Davis, M; Grever, M; McMichael, EL; Mo, X; Otterson, GA; Paul, B; Trikha, P, 2016) |
| "Thalidomide was initiated at 200 mg;3>daily and increased to a target dose of 1000 mg daily." | 2.70 | Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. ( Abbruzzese, JL; El-Naggar, AK; Ginsberg, LE; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Lawhorn, KN; Myers, JN; Pluda, JM; Roach, JS; Shin, DM; Steinhaus, GD; Teddy, S; Thall, PF; Tseng, JE; Wang, X; Zentgraf, RE, 2001) |
| "Thalidomide is an immunomodulatory, antiangiogenic drug." | 1.34 | Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. ( Beckhove, P; Dyckhoff, G; Helmke, BM; Herold-Mende, CC; Kashfi, F; Lemke, B; Lohr, J; Plinkert, PK; Schirrmacher, V; Vasvari, GP, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taylor, RJ | 1 |
| Saloura, V | 1 |
| Jain, A | 1 |
| Goloubeva, O | 1 |
| Wong, S | 1 |
| Kronsberg, S | 1 |
| Nagilla, M | 1 |
| Silpino, L | 1 |
| de Souza, J | 1 |
| Seiwert, T | 1 |
| Vokes, E | 1 |
| Villaflor, V | 1 |
| Cohen, EE | 1 |
| Bertino, EM | 1 |
| McMichael, EL | 1 |
| Mo, X | 1 |
| Trikha, P | 1 |
| Davis, M | 1 |
| Paul, B | 1 |
| Grever, M | 1 |
| Carson, WE | 1 |
| Otterson, GA | 1 |
| Gupta, A | 1 |
| Cohen, BH | 1 |
| Ruggieri, P | 1 |
| Packer, RJ | 1 |
| Phillips, PC | 1 |
| Vasvari, GP | 1 |
| Dyckhoff, G | 1 |
| Kashfi, F | 1 |
| Lemke, B | 1 |
| Lohr, J | 1 |
| Helmke, BM | 1 |
| Schirrmacher, V | 1 |
| Plinkert, PK | 1 |
| Beckhove, P | 1 |
| Herold-Mende, CC | 1 |
| Tseng, JE | 1 |
| Glisson, BS | 1 |
| Khuri, FR | 1 |
| Shin, DM | 1 |
| Myers, JN | 1 |
| El-Naggar, AK | 1 |
| Roach, JS | 1 |
| Ginsberg, LE | 1 |
| Thall, PF | 1 |
| Wang, X | 1 |
| Teddy, S | 1 |
| Lawhorn, KN | 1 |
| Zentgraf, RE | 1 |
| Steinhaus, GD | 1 |
| Pluda, JM | 1 |
| Abbruzzese, JL | 1 |
| Hong, WK | 1 |
| Herbst, RS | 1 |
4 trials available for thalidomide and Head and Neck Neoplasms
| Article | Year |
|---|---|
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; C | 2016 |
Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Cohort Studies; Dermatologic Agents; Dose-Respons | 2003 |
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Squamous C | 2001 |
1 other study available for thalidomide and Head and Neck Neoplasms
| Article | Year |
|---|---|
Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2007 |